Clinical relevance and management of drug-related QT interval prolongation

Pharmacotherapy

Volumn 23, Issue 7, 2003, Pages 881-908

  Crouch, Michael A ^a   Limon, Lynn ^b   Cassano, Angela T ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c CROZER CHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMIODARONE; AMITRIPTYLINE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMIGRAINE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CITALOPRAM; DESIPRAMINE; DISOPYRAMIDE; DOFETILIDE; ENFLURANE; FELBAMATE; FLECAINIDE; FOSPHENYTOIN SODIUM; GASTROINTESTINAL AGENT; HALOTHANE; IBUTILIDE; ISOFLURANE; NEUROLEPTIC AGENT; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; UNINDEXED DRUG;

CARDIOTOXICITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG FATALITY; DRUG MECHANISM; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; LONG QT SYNDROME; QRS COMPLEX; QT INTERVAL; REVIEW; SIDE EFFECT; ST SEGMENT DEPRESSION; SUDDEN DEATH; SYNCOPE; T WAVE; TORSADE DES POINTES;

DRUG APPROVAL; DRUG INTERACTIONS; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S ROLE; TORSADES DE POINTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037705711     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.7.881.32730     Document Type: Review

References (324)

1. Fisch C. Electrocardiography. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine, 5th ed. Philadelphia: WB Saunders Company, 1997:108-52.
2. Goldberger AL. Electrocardiography. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994:954-65.
3. Malek M, Camm AJ. Evaluation of drug induced QT interval prolongation: implications for drug approval and labeling. Drug Saf 2001;24:323-61.
4. Drici MD, Knollman BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998;280:1774-8.
5. Viskin S. Long QT syndromes and torsades de pointes. Lancet 1999;354:1625-33.
6. Laakso M, Aberg A, Savola J, Pentikainen P, Pyorala K. Diseases and drugs causing prolongation of the QT interval. Am J Cardiol 1987;59:862-5.
7. Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 1998;73:250-69.
8. Drici MD. Influence of gender on drug-acquired long QT syndrome. Eur Heart J 2001;3(suppl K):K41-7.
9. Haverkamp W, Eckardt L, Monnig G, et al. Clinical aspects of ventricular arrhythmias associated with QT prolongation. Eur Heart J 2001;3(suppl K):K81-8.
10. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsades de pointes. Drug Saf 2002;25:263-86.
11. Baxter Healthcare Corporation Ethrane (enflurane) package insert. Deerfield, IL; 2001.
12. Wyeth Ayerst. Fluothane (halothane) package insert. Philadelphia, PA; 2000.
13. Baxter Pharmaceutical Products Inc. Isoflurane [generic] package insert. New Providence, NJ; 2000.
14. Wyeth Laboratories. Cordarone (amiodarone) package insert. Philadelphia, PA; 1999.
15. Fujisawa Healthcare, Inc. Adenocard (adenosine) package insert. Deerfield, IL; 2000.
16. G. D. Searle. Norpace (disopyramide) package insert. Chicago, IL; 1999.
17. Pfizer, Inc. Tikosyn (dofetilide) package insert. New York, NY; 1999.
18. 3M Pharmaceuticals. Tambocor (flecainide) package insert. Northridge. CA; 1998.
19. Pharmacia and Upjohn Company. Corvert (ibutilide) package insert. Kalamazoo, MI; 1999.
20. Apothecon. Pronestyl (procainamide) package insert. Princeton, NJ; 1991.
21. Knoll Pharmaceutical Company. Rythmol (propafenone) package insert. Mount Olive, NY; 1998.
22. A. H. Robins Company. Quinidex Extentabs (quinidine extended release) package insert. Richmond, VA, 1998.
23. Berlex Laboratories. Betapace (sotalol) package insert. Wayne, NJ; 2000.
24. Wallace Laboratories. Felbatol (felbamate) package insert. Cranbury, NJ; 1999.
25. Parke Davis. Cerebyx (fosphenytoin) package insert, Morris Plains, NJ; 1999.
26. Mylan Pharmaceuticals, Inc. Amitriptyline [generic] package insert. Morgantown, WV; November 2000.
27. Forest Laboratories, Inc. Celexa (citalopram) package insert. St. Louis, MO; 2000.
28. Aventis Pharmaceuticals. Norpramin (desipramine) package insert. Parsippany, NJ; 1997.
29. Pfizer, Inc. Sinequan (doxepin) package insert. New York, NY; 1996.
30. Dista Products Company. Prozac (fluoxetine) package insert. Indianapolis, IN; 2001.
31. Geneva Pharmaceuticals, Inc. Imipramine [generic] package insert. Broomfield, CT; 1999.
32. Mylan Pharmaceuticals, Inc. Maprotiline [generic] package insert. Morgantown, WV; 2001.
33. Watson Laboratories, Inc. Nortriptyline [generic] package insert. Corona, CA; 2001.
34. GlaxoSmithKline. Paxil (paroxetine) package insert. Research Triangle Park, NC; 2002.
35. Pfizer, Inc. Zoloft (sertraline) package insert. New York, NY; 2001.
36. Wyeth Laboratories. Effexor (venlafaxine) package insert. Philadelphia, PA; 2001.
37. Geneva Pharmaceuticals, Inc. Clemastine [generic] package insert. Broomfield, CT; 2000.
38. Major Pharmaceuticals. Diphenhydramine [generic] package insert. Livonia, MI; 2001.
39. Schering Corporation. Claritin (loratadine) package insert. Kenilworth, NJ; 2000.
40. Abbott Laboratories. Biaxin (clarithromycin) package insert North Chicago, IL; 2000.
41. Abbott Laboratories. Erythromycin lactobionate i.v. [generic] package insert. North Chicago, IL; 1992.
42. Pfizer, Inc. Diflucan (fluconazole) package insert. New York NY; 1998.
43. Astra Zeneca Pharmaceuticals LP. Foscavir (foscarnet) package insert. Wilmington, DE; 1999.
44. Roche Laboratories Inc. Cytovene (ganciclovir) package insert. Nutley, NJ; 2000.
45. Bristol-Myers Squibb. Tequin (gatifloxacin) package insert. Princeton, NJ; 2000.
46. GlaxoSmithKline. Halfan (halofantrine) package insert. Research Triangle Park, NC; 2001.
47. Janssen Pharmaceutica Products. Sporanox (itraconazole capsules) package insert. Titusville, NJ; 2000.
48. Janssen Pharmaceutica Products. Sporanox (itraconazole oral solution) package insert. Titusville, NJ; 2000.
49. Janssen Pharmaceutica Products. Sporanox (itraconazole injection) package insert. Titusville, NJ; 2000.
50. Janssen Pharmaceutica Products. Nizoral (ketoconazole) package insert. Titusville, NJ; 1998.
51. Ortho-McNeil Pharmaceuticals. Levaquin (levofloxacin) package insert. Raritan, NJ; 2000.
52. Roche Laboratories Inc. Lariam (mefloquine) package insert. Nutley, NJ; 1999.
53. Bayer Corporation. Avelox (moxifloxacin) package insert. West Haven, CT; 2001.
54. American Pharmaceutical Partners. Nebupent (pentamidine) package insert. Los Angeles, CA; 1999.
55. Roche Laboratories Inc. Bactrim (trimethoprimsulfamethoxazole) package insert. Nutley, NJ; 2000.
56. GlaxoSmithKline. Thorazine (chlorpromazine) package insert. Research Triangle Park, NC; 2000.
57. Ortho-McNeil Pharmaceutical, Inc. Haldol (haloperidol) package insert. Raritan, NJ; October 1998.
58. Boehringer Ingelheim Pharmaceuticals, Inc. Serentil (mesoridazine) package insert. Ridgefield, CT; 2001.
59. Gate Pharmaceuticals. Orap (pimozide) package insert. Sellersville, PA; 1999.
60. Astra Zeneca Pharmaceuticals LP. Seroquel (quetiapine) package insert. Wilmington, DE; 2001.
61. Janssen Pharmaceutica Products. Risperdal (risperidone) package insert. Titusville, NJ; 2000.
62. Novartis Pharmaceutical Corporation. Clozaril (clozapine) package insert. East Hanover, NJ; 2001.
63. Novartis Pharmaceutical Corporation. Mellaril (thioridazine) package insert. East Hanover, NJ; 2000.
64. Pfizer, Inc. Geodon (ziprasidone) package insert. New York, NY. July 2002.
65. Cell Therapeutics, Inc. Trisenox (arsenic trioxide) package insert. Seattle, WA; 2000.
66. Astra Zeneca Pharmaceuticals LP. Nolvadex (tamoxifen) package insert. Wilmington, DE; 1999.
67. Ortho-McNeil Pharmaceuticals, Inc. Vascor (bepridil) package insert. Raritan, NJ; 2000.
68. Mylan Pharmaceuticals, Inc. Indapamide [generic] package insert. Morgantown, WV; 1998.
69. Reliant Pharmaceuticals LLC. DynaCirc (istadipine) package insert. Liberty Corner, NJ; 2000.
70. Schwarz Pharma, Inc. Uniretic (moexpril/hydrochlorothiazide) package insert. Meguon, WI; 2000.
71. Wyeth Laboratories. Cardene (nicardipine) package insert. Philadelphia, PA; 1996.
72. Novartis Pharmaceuticals Corporation. Sandostatin (octreotide) package insert. East Hanover, NJ; 1999.
73. Abbott Laboratories. Droperidol [generic] package insert. North Chicago, IL; 1995.
74. Aventis Pharmaceuticals, Inc. Anzemet (dolasetron) package insert. Kansas City, MO; 1999.
75. GlaxoSmithKline. Amerge (naratriptan) package insert. Research Triangle Park, NC; 1999.
76. GlaxoSmithKline. Imitrex (sumatriptan) package insert. Research Triangle Park, NC; 2001.
77. Merck and Co., Inc. Maxalt (rizatriptan) package insert. West Point, PA; 2000.
78. Astra Zeneca Pharmaceuticals LP. Zomig (zolmitriptan) package insert. Wilmington, DE; 2000.
79. American Regent Laboratories, Inc. Epinephrine [generic] package insert. Shirley, NY; June 1999.
80. Roxane Laboratories, Inc. Orlaam (levomethadyl) package insert. Columbus, OH; 2000.
81. Roxane Laboratories, Inc. Dolophine (methadone) package insert. Columbus, OH; 2001.
82. GlaxoSmithKline. Serevent (salmeterol) package insert. Research Triangle Park, NC; 2000.
83. Fujisawa Healthcare, Inc. Prograf (tacrolimus) package insert. Deerfield Park, IL; 2001.
84. Elan Pharmaceuticals Inc. Zanaflex (tizanidine) package insert. South San Francisco, CA; 2000.
85. Schmeling WT, Warltier DC, McDonald DJ, Madsen KE, Atlee JL, Kampine JP. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137-44.
86. Guler N, Kati I, Demirel CB, Bilge M, Eryonucu B, Topal C. The effects of volatile anesthetics on the QTc interval. J Cardiothorac Vasc Anesth 2001;15:188-91.
87. Michaloudis D, Fraidakis O, Lefaki T, Kanakoudis F, Askitopoulou H. Anaesthesia and the QT interval in humans: effects of halothane and isoflurane in premedicated children. Eur J Anaesthesiol 1998;15:623-8.
88. Wright CJ. Dysrhythmias during oral surgery: a comparison between halothane and enflurane anaesthesia. Anaesthesia 1980;35:775-8.
89. Barker GL, Briscoe CE. The pathfinder high-speed ECG analyzer: use in detection of arrhythmias during oral surgery. Br J Anaesth 1981;53:1079-82.
90. Lindgren L. ECG changes during halothane and enflurane anaesthesia for ENT surgery in children. Br J Anaesth 1981;52:653-62.
91. Imamura S, Hashimoto H, Ikeda K, Nakashima M. Effects of volatile anaesthetics enflurane, isoflurane, and halothane on ventricular delayed activation in canine myocardial infraction model. J Electrocardiol 1994;27:41-8.
92. Hief C, Borggrefe M, Chen X, et al. Effect of enflurane on inducibility of ventricular tachycardia. Am J Cardiol 1991;68:609-13.
93. Doig JC. Drug-induced cardiac arrhythmias: incidence, prevention, and management. Drug Saf 1997;17:265-75.
94. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997;80:G82-9.
95. Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000;23:509-32.
96. Thomas SHL. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxciol Rev 1994;13:77-102.
97. Lazzara R. Antiarrhythmic drugs and torsades de pointes. Eur Heart J 1993;14(suppl H):88-92.
98. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de points. Eur Heart J 2001;3(suppl K):K70-80.
99. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
100. Nathan AW, Hellestrand KJ, Bexton RS, Spurrell RA, Camm AJ. The proarrhythmic effects of flecainide. Drugs 1985;29(suppl 4):45-53.
101. Sarubbi B, Ducceschi V, Briglia N, Mayer MS, Santangelo L, Iacono A. Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease. Int J Cardiol 1998;66:157-64.
102. Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63:342-4.
103. Katritsis D, Rowland E, O'Nunain S, Shakespeare CF, Poloniecki J, Camm AJ. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Eur Heart J 1995;16:1930-5.
104. Soyka LF, Wirtz C, Spengenburg RB. Clinical safety profile of sotalol in patients with arrhythmia. Am J Cardiol 1990;65:A74-81.
105. Hohnloser SH, Arendts W, Quart B. Incidence, type, and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF [letter]. Pacing Clin Electrophysiol 1992;15:173.
106. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex differences in risk of torsades de pointes with d,1 sotalol. Circulation 1996;94:2534-41.
107. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia. Ann Intern Med 1994;121:529-35.
108. Jafari-Fesharaki M, Scheinman MM. Adverse effects of amiodarone. Pacing Clin Electrophysiol 1998;21:108-20.
109. Howard PA. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother 1999;33:38-47.
110. Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S. Adenosine induced torsades de pointes in a child with congenital long QT syndrome. Pacing Clin Electrophysiol 1994;17:1814-7.
111. Smith JR, Goldberger JJ, Kadish AH. Adenosine induced polymorphic ventricular tachycardia in adults without structural heart disease. Pacing Clin Electrophysiol 1997;20:743-5.
112. Crome P. Antidepressant overdosage. Drugs 1982;23:431-61.
113. Thorstrand C. Clinical features in poisonings by tricyclic antidepressants with special reference to the ECG. Acta Medica Scandinavica 1976;199:337-44.
114. Starkey IR, Lawson AH. Poisoning with tricyclic and related antidepressants: a ten-year review. Quar J Med 1980; NS49:33-49.
115. Siddiqui JH, Vakassi MM, Ghani MF. Cardiac effects on amitriptyline overdose. Curr Ther Res 1977;22:321-5.
116. Herrmann HC, Kaplan LM, Bierer BE. QT prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983;81:904-6.
117. Leonard HL, Meyer MC, Swedo S, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry 1995;34:1460-8.
118. Biederman J, Baldessarini RJ, Goldblatt A, et al. A naturalistic study of 24-hour electrocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993;32:805-13.
119. Riddle MA, Geller B, Ryan N. Another sudden death in a child with desipramine. J Am Acad Child Adolesc Psychiatry 1993;32:792-7.
120. Baker B, Dorian P, Sandon P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997;17:15-21.
121. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QTc abnormalites and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-52.
122. Teschemacher AG, Seward E, Hancox JC, Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 1999;128:479-85.
123. Pacher P, Ungvari Z, Nanasi PP, Furst S, Keeskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects: is there any? Curr Med Chem 1999;6:469-80
124. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985;46:42-4.
125. Appleby M, Mbewu A, Clarke B. Fluoxetine and ventricular torsades: is there a link? Int J Cardiol 1995;49:178-80.
126. Varriale P. Fluoxetine (Prozac) as a cause of QT prolongation [letter]. Arch Intern Med 2001;161:612.
127. Lherm T, Lottin F, Larbi D, Bray M, Legall C, Caen D. Torsades de pointes after poisoning with fluoxetine alone. Presse Med 2000;29:306-7.
128. Erfurth A, Loew M, Dobmeier P, Wendler G. ECG changes after paroxetine: 3 case reports. Nervenarzt 1998;69:629-31.
129. Hoehns JD, Fouts MM, Kelly MW, Tu KB. Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother 2001;35:862-6.
130. Personne M, Sjoberg G, Persson H. Citalopram overdose: review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997;35:237-40.
131. Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001;20:215-9.
132. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
133. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
134. Zimmermann M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992;13:1002-3.
135. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
136. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996;59:383-8.
137. Clark A, Love H. Astemizole-induced ventricular arrhythmias: an unexpected case of convulsions. Int J Cardiol 1991;33:165-7.
138. Wiley JF, Gelber ML, Henretig FM, Wiley CC, Sandhu S, Loiselle J. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992;120:799-802.
139. Berul CI, Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation 1995;91:2220-5.
140. Zareba W, Moss AJ, Rosero SZ, Hajj-Ali R, Konecki J, Andrews M. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997;80:1168-73.
141. 1 receptor antagonists on action potentials in guinea-pig isolated papillary muscles. Arch Int Pharmacodyn Ther 1996;331:59-73.
142. + channels. J Cardiovasc Pharmacol 1997;30:42-54.
143. de Abajo FJ, Rodriguez LA. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 1999;47:307-13.
144. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8.
145. Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999;57:31-47.
146. 1 receptor antagonist: 2nd communication - lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000;50:441-8.
147. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-44.
148. Tschida SJ, Guay DR, Straka RJ, Hoey LL, Johanning R, Vance-Bryan K. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 1996;16:663-74.
149. Katapadi K, Kostandy G, Katapadi M, Hussain KM, Schifter D. A review of erythromycin-induced malignant tachyarrhythmia- torsades de pointes: a case report. Angiology 1997;48:821-6.
150. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism Am J Med 1990;89:235-8.
151. Lin JC, Quesny HA. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy 1997;17:626-30.
152. McComb J, Campbell N, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1984;54:922-3.
153. Rezkalla M, Pochop C. Erythromycin induced torsades de pointes: case report and review of the literature. S D J Med 1994;47:161-4.
154. Guelon D, Bedock B, Chartier C, Haberer J. QT prolongation and recurrent 'torsades de pointes' during erythromycin administration [letter]. Am J Cardiol 1986;58:666.
155. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 1994;105:368-72.
156. Chennareddy SB, Siddique M, Karim MY, Kudesia V. Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Am Heart J 1996;132:691-4.
157. Haefelli W, Schoenenberger R, Weiss P, Ritz R. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med 1992;18:469-73.
158. Oberg KC, Bauman JL. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995;15:687-92.
159. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest 1999;115:983-6.
160. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration adverse event reporting system. Clin Infect Dis 2002;35:197-200.
161. Tie H, Walker BD, Singleton CB, et al. Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br J Pharmacol 2000;140:1967-75.
162. Monlun E, Le Metayer P, Szwandt S, et al. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg 1995;89:430-3.
163. Monlun E, Pillet O, Cochard JF, Garrigues JCF, Le Bras M. Prolonged QT interval with halofantrine. Lancet 1993;341:1541-2.
164. Castot A, Rapport P, Le Coz P. Prolonged QT interval with halofantrine [letter]. Lancet 1993;341:1541.
165. Toivonen L, Vitasalo M, Silkamaki H, Raatikka M, Pohjola-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol 1994;17:403-4.
166. Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE, Wortham DC. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 1994;105:389-95.
167. Cortese LM, Gasser RA, Bjornson DC, Dacey MJ, Oster CN. Prolonged recurrence of pentamidine-induced torsades de pointes. Ann Pharmacother 1992;26:1365-9.
168. Wharton JM, Demopulos PA, Goldschlager N. Torsades de pointes during administration of pentamidine isethionate. Am J Med 1987;83:571-6.
169. Lindsay J, Smith MA, Light JA. Torsades de pointes associated with antimicrobial therapy for pneumonia. Chest 1990;98:222-3.
170. Zanetti LA, Oliphant CA. Pentamidine-induced torsades de pointes. Ann Pharmacother 1994;28:282-3.
171. Mitchell P, Dodek P, Lawson L, Kiess M, Russell J. Torsades de pointes during intravenous pentamidine isethionate therapy. Can Med Assoc J 1989;140:173-4.
172. Stein KM, Haronian H, Mensah GA, Acosta A, Jacobs J, Kligfield P. Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii in the acquired immunodeficiency syndrome. Am J Cardiol 1990;66:888-9.
173. Bibler MR, Chou TC, Toltzis RJ, Wade PA. Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity Chest 1988;94:1303-6.
174. Pujol M, Carratala J, Mauri J, Viladrich PF. Ventricular tachycardia due to pentamidine isethionate [letter]. Am J Med 1988;84:980.
175. Girgis I, Gualberti J, Langan L, et al. A prospective study of the effect of IV pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 1997;112:646-53.
176. Gonzalez A, Sager PT. Pentamidine-induced torsades de pointes. Am Heart J 1991;122:1489-92.
177. Taylor AJ, Hull RW, Coyne PE, et al. Pentamidine-induced torsades de pointes: sale completion of therapy with inhaled pentamidine. Clin Pharmacol Ther 1991;49:698-700.
178. Thalhammer C, Bogner JR, Lohmoller G. Chronic pentamidine aerosol prophylaxis does not induce QT prolongation. Clin Investig 1993;71:319-22.
179. Engrav MB, Coodley G, Magnusson AR. Torsades de pointes after inhaled pentamidine. Ann Emerg Med 1992;21:1404-5.
180. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin: sparfloxacin safety group. J Antimicrob Chemother 1996;37:161-7.
181. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999;58:37-42.
182. Ball P. Quinolone-induced QT interval prolongation: a nonso-unexpected class effect. J Antimicrob Chemother 2000;45:557-9.
183. Anonymous. The pink sheet. Bayer Avelox cardiac safety studies recommended by FDA committee. Chevy Chase, MD: FDC Reports, Inc., 1999;61(43):4.
184. Anonymous. The pink sheet. FDA/PHRMA task force to assess QT risk by preclinical markers. Chevy Chase, MD: FDC Reports, Inc., 1999;61(44):15.
185. + channel HERG. Mol Pharmacol 2001;59:122-6.
186. Von Keutz E, Schluter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 1999;43(suppl B):91-100.
187. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000;59:115-39.
188. Hollister AS, Haverstock D, Choudri S. Moxifloxacin has a favorable cardiovascular safety profile in patients taking concomitant QTc prolonging drug [abstr] In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2000:476.
189. Kubin R, Reiter C. Safety update of moxifloxacin: a review of clinical trials and worldwide post-marketing surveillance [abstr] In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2000:477.
190. Sacks L. A review of the safety of moxifloxacin hydrochloride: March 6, 2000. Available from www.fda.gov/ohrms/dockets/ ac/99/slides/3558s1g/sld001.htm. Accessed July 15, 2002.
191. Iannini PB, Seggern K, Wikler MA. Safety of gatifloxacin in patients with cardiovascular disease. [abstr] In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology. 2000:469.
192. Bristol-Myers Squibb. Data on file. Princeton, NJ; 2001.
193. Iannini PB, Circiumaru I. Gatifloxacin-induced QTc-prolongation and ventricular tachycardia. Pharmacotherapy 2001;21:361-2.
194. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-72.
195. Dresser GK, Spence D, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
196. Piquette RK. Torsades de pointes induced by cisaprideclarithromycin interactions. Ann Pharmacother 1999;33:22-6.
197. Lee KL, Jim MH, Tang SC, Tai YT. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998:104:395-6.
198. Kamochi H, Nii T, Eguchi K, et al. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999;63:421-2.
199. Zehender M, Hohnloser, S, Just H. QT prolonging drugs: mechanisms and clinical relevance of the arrhythmogenic hazards. Cardiovasc Drugs Ther 1991;5:515-30.
200. Shaffer DN, Singer SJ. Macrolide antibiotics and torsades de pointes postmarketing analysis. Telithromycin Advisory Committee. April 26, 2001. Available from http://www. fda.gov/ohrms/dockets/ac/01/slides/3746s_02_shaffer_rev/. Accessed September 16, 2002.
201. Dumaine R, Roy ML, Brown Am. Blockade of HERG and Kvl.5 by ketoconazole. J Pharmacol Exp Ther 1998;286:727-35.
202. Paserchia LA, Hewett J, Woosley RL. Effects of ketoconazole on QTc [abstr]. Clin Pharmacol Ther 1994;55:146.
203. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsades-de pointes. Ann Pharmacother 2001;35:432-4.
204. Wassman S, Nickenig G, Bohm M. Long QT syndrome and torsades de pointes in a patient receiving fluconazole [letterl. Ann Intern Med 1999;131:797.
205. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol 1983;5:173-5.
206. Martin ES, Rogalski K, Black JN. Quinine may trigger torsades de pointes during astemizole therapy. Pacing Clin Electrophysiol 1997;20:2024-5.
207. Cohen AJ, Weiser B, Afzal Q, Fuhrer J. Ventricular tachycardia in two patients with AIDS receiving ganciclovir (DHPG). AIDS 1990;4:807-9.
208. Samaha FF. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 1999;107:528-9.
209. Weiner I, Rubin DA, Martinez E, Postman J, Herman MV. QT prolongation and paroxysmal ventricular tachycardia occurring during fever after trimethoprim-sulfamethoxazole administration. Mt Sinai J Med 1981;48:53-5.
210. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT Prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 1987;59:376-7.
211. Sesti E, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000;97:10613-8.
212. Laothavorn P, Karbwang J, Na Bangchang K, Bunnag D, Harinasuta T. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients. Southeast Asian J Trop Med Public Health 1992;23:51-4.
213. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993;341:1054-6.
214. Jaspers CA, Hopperus Buma AP, van Thiel PP, van Hulst RA, Kager PA. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996;55:230-4.
215. Lightbown ID, Lambert JP, Edwards G, Coker SJ. Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine. Br J Pharmacol 2001;132:197-204.
216. Kang J, Chen XL, Wang L, Rampe D. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther 2001;299:290-6.
217. Kang J, Wang L, Cai F, Rampe D. High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. Eur J Pharmacol 2000;392:137-40.
218. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997;120:968-74.
219. Drolet B, Zhang S, Deschenes D. Droperidol lengthens cardiac repolarization due to the block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 1999;10:1597-1604.
220. Douglas PH, Block PC. Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. Catheter Cardiovasc Interv 2000;50:352-5.
221. Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth 2000;47:251-4.
222. O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsades de pointes. Ann Pharmacother 199933:1046-50.
223. Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993;13:128-32.
224. Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, Kishon Y. Haloperidol-induced torsades de pointes. Chest 1990;98:482-4.
225. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997;17:531-7.
226. Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000;20:317-24.
227. Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 1995;309:315-6.
228. Alexander CS, Nino A. Cardiovascular complications in young patients taking psychotropic drugs: a preliminary report. Am Heart J 1969;78:757-69.
229. Arita M, Surawicz B. Electrophysiologic effects of thioridazine on canine cardiac fibers. J Pharmacol Exp Ther 1973;184:619-30.
230. DeSautels S, Filteau C, St. Jean A. Ventricular tachycardia with administration of thioridazine hydrochloride. Canad Med Assoc J 1964;90:1030-1.
231. Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976;37:223-30.
232. Giles TD, Modlin RK. Death associated with ventricular arrhythmia and thioridazine hydrochloride. JAMA 1968;205:98-100.
233. Hollister LE, Kosik JC. Sudden death during treatment with phenothiazine derivatives. JAMA 1965;192:1035-8.
234. Kelly HG, Fay JE, Laverty SG. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Canad Med Assoc 1963;89:546-54.
235. Kemper AJ, Dunlap R, Pietro DA. Thioridazine-induced torsades de pointes. JAMA 1983;249:2931-4.
236. Kiriike N, Maeda Y, Nishiwaki S, et al. Iatrogenic torsades de pointes induced by thioridazine. Biol Psychiatry 1987;22:99-103.
237. Schoonmaker FW, Osteen RT, Greenfield JC. Thioridazine (Mellaril)-induced ventricular tachycardia controlled with an artificial pacemaker. Ann Intern Med 1966;65:1076-8.
238. Sydney MA. Ventricular arrhythmias associated with use of thioridazine hydrochloride in alcohol withdrawal [letter]. Br Med J 1973;4:467.
239. Yoon MS, Han J, Dersham GH, Jones SA. Effects of thioridazine (Mellaril) on ventricular electrophysiolgic properties. Am J Cardiol 1979;43:1155-8.
240. Drolet B, Vincent F, Rail J, et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed
241. Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996;60:543-53.
242. Novartis Pharmaceutical Corporation. Dear doctor or pharmacist letter. East Hanover, NJ: Novartis Pharmaceutical Corporation, July 2000. Available from http://www.fda.gov/ medwatch/safety/2000/mellar.htm. Accessed July 15, 2002.
243. Novartis Pharmaceutical Corporation. Dear doctor or pharmacist letter. East Hanover, NJ: Novartis Pharmaceutical Corporation, September 2000. Available from www.fda.gov/ medwatch/safety/2000/serent.htm. Accessed July 15, 2002.
244. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
245. Anonymous. The pink sheet, Pfizer's ziprasidone labeling stops short of second-line use; QT effect noted. Chevy Chase, MD: FDC Reports, Inc., 2001;63:9.
246. Anonymous. The pink sheet. Zeldox: Swedish contraindications include prolonged QT interval. Chevy Chase, MD: FDC Reports, Inc., 1998;60:13.
247. Ochiai H, Kashiwagi M, Usui T, Oyama Y, Tokita Y, Ishikawa T. Torsades de pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: report of a case. Kokyu To Junkan 1990;38:819-22.
248. Ng AS, Johan A, Chia BL, Nadarajah K. Chlorpromazine induced T wave and QT alterans: a case report and review. Singapore Med J 1982;23:110-3.
249. Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976;37:223-30.
250. Wendkos MH. Cardiac changes related to phenothiazine therapy, with special reference to thioridazine. J Am Geriatr Soc 1967;15:20-8.
251. Gajwani P, Pozuelo L, Tesar GE. QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 2000;41:63-5.
252. Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001;20:215-9.
253. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998;18:477-81.
254. Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000;25:154-60.
255. Litherland S. Drug treatment and schizophrenia in the 1990s [letter]. Drugs 1997;54:794.
256. Goldsmith S, From AH. Arsenic-induced atypical ventricular tachycardia. N Engl J Med 1980;303:1096-8.
257. Klaassen CA. Heavy metal and heavy-metal antagonists. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 9th Ed. New York: McGraw-Hill Health Professionals Division, 1996:1649-71.
258. Unnikrishnan D, Dutcher JP, Varshneya N. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001;97:1514-16.
259. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2001;133:881-5.
260. Kr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 1998;287:877-83.
261. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992;84:1811-16.
262. Manouvrier J, Sagot M, Caron C, et al. Nine cases of torsades de pointes with bepridil administration. Am Heart J 1986;111:1005-7.
263. Pinaud D, Chabanier A, Vergnoux H, et al. Bepridil and torsades de pointes: apropos of 11 cases. Ann Cardiol Angeiol (Paris) 1987;36:421-5.
264. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 1998;54:695-703.
265. Manouvrier J, Sagot M, Carson C, et al. Nine cases of torsades de pointes with bepridil administration. Am Heart J 1986;5:1005-7.
266. Funck-Brentano C, Coudray P, Planellas J, Motte G, Jaillon P. Effects of bepridil and diltiazem on ventricular repolarization in anginal pectoris. Am J Cardiol 1990;66:812-7.
267. Prystowsky EN. Effects of bepridil on cardiac electrophysiologic properties. Am J Cardiol 1992;69:D63-7.
268. Klein L. QT interval prolongation produced by probucol. Arch Intern Med 1981;141:1102-3.
269. Troendle G, Guerigian J, Sobel S, Johnson M. Probucol and the QT interval [letter]. Lancet 1982;1:1179.
270. McCaughan D. Probucol and the QT interval [letter]. Lancet 1982;2:161.
271. Dujovne CA, Atkins F, Wong B, DeCoursey S, Krehbiel P, Chernoff SB. Electrocardiographic effects of probucol: a controlled prospective clinical trial. Eur J Clin Pharmacol 1984;26:735-9.
272. Browne KF, Prystowsky EN, Heger JJ, Cerimele BJ, Fineberg N, Zipes DP. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug. Am Heart J 1984;107:680-4.
273. Jones DB, Simpson HC, Slaughter P, et al. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia. Atherosclerosis 1984;53:1-7.
274. Strandberg TE, Vanhanen H, Miettinen TA. Probucol in long-term treatment of hypercholesterolemia. Gen Pharmacol 1988;19:317-20.
275. Matsuhashi H, Onodera S, Kawamura Y, et al. Probucol-induced QT prolongation and torsades de pointes. Jpn J Med 1989;28:612-5.
276. Tamura M, Ueki Y, Ohtsuka E, et al. Probucol-induced QT prolongation and syncope. Jpn Circ J 1994;58:374-7.
277. Ohya Y, Kumamoto K, Abe I, Tsubota Y, Fujishima M. Factors related to QT interval prolongation during probucol treatment. Eur J Clin Pharmacol 1993;45:47-52.
278. Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 1996;131:1184-91.
279. Meinertz T. Mibefradil: a drug which may enhance the propensity for the development of abnormal QT prolongation. Eur Heart J 2001;3(suppl K):K89-92.
280. Guzzini F, Baroffio R, Coppetti D, Gasparini P. Severe ventricular arrhythmias secondary to indapamide- induced hypokalemia. Clin Ter 1990;135:283-7.
281. Cosma C, Pauly C, Py C. Torsades de pointes induced by concurrent indapamide and disopyramide administration [letter]. Nouv Presse Med 1978;7:3455.
282. + current, by the diuretic agent indapamide in the guinea pig myocytes. Circ Res 1994;75:879-86.
283. Tullo NG, Landau S, Goldman I, Coutinho N, Somberg J. A randomized comparative study of the electrophysiological and electrocardiographic effects of isradipine vs verapamil. Acta Anaesthesiol Scand 1993;99:43-7.
284. Gheorghiade M, St Clair C, St Clair J, Freedman D, Schwemer G. Short- and long-term treatment of stable effort angina with nicardipine, a new calcium channel blocker: a double-blind, placebo - controlled, randomised, repeated cross-over study. Br J Clin Pharmacol 1985;20(suppl 1):195S-205.
285. Schwartz AB, Moskowitz RM, Klausner SC. The electrophysiologic effects of nicardipine hydrochloride in man. Can J Cardiol 1987;3:14-17.
286. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000;39:49-75.
287. Anonymous. FDA talk paper. January 24, 2000. FDA updates warnings for cisapride. Available from www.fda.gov/bbs/ topics/ANSWERS/ANS00999.html. Accessed July 15, 2002.
288. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997;282:220-7.
289. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
290. Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994;79:983-6.
291. Anonymous. FDA talk paper. December 5, 2001. FDA strengthens warnings for droperidol. Available from www.fda.gov/bbs/topics/ANSWERS/2001/ANS01123.html. Accessed July 15, 2002.
292. Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 2000;295:614-20.
293. 1-receptor agonist, on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-6.
294. Jhee SS, Salazar DE, Ford NF, Fulmor IE, Sramek JJ, Cutler NR. Monitoring of acute migraine attacks: placebo response and safety data. Headache 1998;38:35-8.
295. Lloyd K. The clinical profile of sumatriptan: safety and tolerability Eur Neurol 1994;34:40-3.
296. Laine K, Raasakka T, Mantynen J, Saukko P. Fatal cardiac arrhythmia after oral sumatriptan. Headache 1999;39:511-2. 297.
297. Pharmacia. Axert (almotriptan) package insert. Kalamazoo, MI; 2001.
298. + currents. J Pharmacol Exp Ther 2002;303:688-94.
299. Krantz MJ, Lewkowiez L, Hays H, Woodoffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-4.
300. Johansson BW, Hansen O, Juul-Moller S, Svensson O. Adrenaline-induced changes in serum electrolytes, ECG, and blood pressure, with Ca-blockade pretreatment. Angiology 1988;39:345-54.
301. Richardson MG, Roark GL, Helfaer MA. Intraoperative epinephrine-induced torsades de pointes in a child with long QT syndrome. Anesthesiology 1992;76:647-9.
302. Kawade M, Ohe T, Kamiya T. Provocative testing and drug response in a patient with the long QT syndrome. Br Heart J 1995;74:67-70.
303. Shimizu W, Ohe T, Kurita T, et al. Effects of verapamil and propranolol on early after depolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 1995;26:1299-309.
304. Sun ZH, Swan H, Viitasalo M, Toivonen L. Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome. J Am Coll Cardiol 1998;31:1400-5.
305. Johnson MC, So S, Marsh JW, Murphy AM. QT prolongation and torsades de pointes after administration of FKS06. Transplantation 1992;53:929-30.
306. Hodak SP, Moubarak JB, Rodriguez I, Gelfand MC, Alijani MR, Tracy CM. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation 1998;66:535-7.
307. + currents in rat ventricular myocytes. J Physiol Lond 1997;501:509-16.
308. Bagnato GF, Mileto A, Gulli S, et al. Acute cardiovascular effects of salmeterol in subjects with stable bronchial asthma. Monaldi Arch Chest Dis 1996;51:275-8.
309. Tunaoglu FS, Turktas I, Olgunturk R, Demirsoy S. Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children. Pediatr Int 1999;41:28-31.
310. Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000;23:509-32.
311. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000;34:495-513.
312. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998;32:915-28.
313. Bauman JL. The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome. Eur Heart J 2001;3(suppl K):K93-100.
314. Johnson MD, Newkirk G, White JR. Clinically significant drug interactions. Postgrad Med 1999;105:193-22.
315. Botstein P. Is QT prolongation harmful? A regulatory perspective. Am J Cardiol 1993;72:B50-2.
316. Josephson ME, Buxton AE, Marchlinski FE. The tachyarrhythmias. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine, 13th ed. New York: McGraw-Hill, 1994:1019-1036.
317. Haverkamp W, Breithardt G, Camm J, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Eur Heart J 2000;21:1216-31.
318. Anonymous. FDA talk paper. February 9, 2000. FDA approves irritable bowel syndrome treatment for women. Available from www.fda.gov/bbs/topics/answers/ANS01003. html. Accessed July 15, 2002.
319. Anonymous. FDA talk paper. November 28, 2000. Glaxo Wellcome decides to withdraw Lotronex from the market. Available from www.fda.gov/bbs/topics/answers/ANS01058. html. Accessed July 15, 2002.
320. Adams C. The fine print: are too many doctors missing safety alerts on drugs? Wall Street Journal. March 24, 2000;sect 2:B1, B4.
321. Wysocki DK, Corken A, Gallo-Torres H, Talarico L, Rodruguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-703.
322. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000;284:3036-9.
323. Anonymous. FDA limits Pfizer Tikosyn use to "highly symptomatic" citing torsades side effect. Health News Daily. 1999;11(192):1.
324. Anonymous. The pink sheet. Pfizer ziprasidone labeling stops short of second-line use; QT effect noted. Chevy Chase, MD: FDC Reports, Inc., 2001;63(7):9-10.